Name: A Neonatal Intravenous Transplant Model for Assessment of Early-Life Immune Activities Against Cancer Cells (Video) | JoVE Journal
Uploaded: 2026-06-26T12:25:00.000+00:00
Duration: 6 min 32 s
Description: Learn a neonatal intravenous transplant model using bioluminescent imaging to study early-life immune modulation against pediatric cancer cells in mice. This method enables reproducible tumor engraftment and longitudinal tracking.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

This work was supported by operating grants from the Canadian Institutes of Health Research to G.S.D.R. (MOP-126122). A.F. was the recipient of a Michael Cuccione Childhood Cancer Research Program (MC3RP) Post-Doctoral Scholarship.

<ol><li>Valent, P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cancer+stem+cell+definitions+and+terminology%3A+the+devil+is+in+the+details%5BTitle%5D)+AND+%22Nat+Rev+Cancer%22%5BJournal%5D)">Cancer stem cell definitions and terminology: the devil is in the details.</a> Nat Rev Cancer. 12 (11), 767-775 (2012).</li>
<li>Hwee, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+systematic+review+and+meta-analysis+of+the+association+between+childhood+infections+and+the+risk+of+childhood+acute+lymphoblastic+leukaemia%5BTitle%5D)+AND+%22Br+J+Cancer%22%5BJournal%5D)">A systematic review and meta-analysis of the association between childhood infections and the risk of childhood acute lymphoblastic leukaemia.</a> Br J Cancer. 118 (1), 127(2018).</li>
<li>Kollmann, T. R., Kampmann, B., Mazmanian, S. K., Marchant, A., Levy, O. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Protecting+the+Newborn+and+Young+Infant+from+Infectious+Diseases%3A+Lessons+from+Immune+Ontogeny%5BTitle%5D)+AND+%22Immunity%22%5BJournal%5D)">Protecting the Newborn and Young Infant from Infectious Diseases: Lessons from Immune Ontogeny.</a> Immunity. 46 (3), 350-363 (2017).</li>
<li>Tsafaras, G. P., Ntontsi, P., Xanthou, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Advantages+and+Limitations+of+the+Neonatal+Immune+System%5BTitle%5D)+AND+%22Front+Pediatr%22%5BJournal%5D)">Advantages and Limitations of the Neonatal Immune System.</a> Front Pediatr. 8, 5(2020).</li>
<li>Basha, S., Surendran, N., Pichichero, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Immune+Responses+in+Neonates%5BTitle%5D)+AND+%22Expert+Rev+Clin+Immunol%22%5BJournal%5D)">Immune Responses in Neonates.</a> Expert Rev Clin Immunol. 10 (9), 1171-1184 (2014).</li>
<li>Levy, O. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Innate+immunity+of+the+newborn%3A+basic+mechanisms+and+clinical+correlates%5BTitle%5D)+AND+%22Nat+Rev+Immunol%22%5BJournal%5D)">Innate immunity of the newborn: basic mechanisms and clinical correlates.</a> Nat Rev Immunol. 7 (5), 379-390 (2007).</li>
<li>Gombash Lampe, S. E., Kaspar, B. K., Foust, K. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Intravenous+Injections+in+Neonatal+Mice%5BTitle%5D)+AND+%22J+Vis+Exp%22%5BJournal%5D)">Intravenous Injections in Neonatal Mice.</a> J Vis Exp. (93), e52037(2014).</li>
<li>Passini, M. A., Wolfe, J. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Widespread+Gene+Delivery+and+Structure-Specific+Patterns+of+Expression+in+the+Brain+after+Intraventricular+Injections+of+Neonatal+Mice+with+an+Adeno-Associated+Virus+Vector%5BTitle%5D)+AND+%22J+Virol%22%5BJournal%5D)">Widespread Gene Delivery and Structure-Specific Patterns of Expression in the Brain after Intraventricular Injections of Neonatal Mice with an Adeno-Associated Virus Vector.</a> J Virol. 75 (24), 12382-12392 (2001).</li>
<li>Wasala, L. P., Hakim, C. H., Yue, Y., Yang, N. N., Duan, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Systemic+Delivery+of+Adeno-Associated+Viral+Vectors+in+Mice+and+Dogs%5BTitle%5D)+AND+%22Methods+Mol+Biol%22%5BJournal%5D)">Systemic Delivery of Adeno-Associated Viral Vectors in Mice and Dogs.</a> Methods Mol Biol. 1937, 281-294 (2019).</li>
<li>Glascock, J. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Delivery+of+Therapeutic+Agents+Through+Intracerebroventricular+%28ICV%29+and+Intravenous+%28IV%29+Injection+in+Mice%5BTitle%5D)+AND+%22J+Vis+Exp%22%5BJournal%5D)">Delivery of Therapeutic Agents Through Intracerebroventricular (ICV) and Intravenous (IV) Injection in Mice.</a> J Vis Exp. (56), e2968(2011).</li>
<li>Farrokhi, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Early-life+infection+depletes+preleukemic+cells+in+model+of+hyperdiploid+B-cell+acute+lymphoblastic+leukemia%5BTitle%5D)+AND+%22Blood%22%5BJournal%5D)">Early-life infection depletes preleukemic cells in model of hyperdiploid B-cell acute lymphoblastic leukemia.</a> Blood. 144 (8), 809-821 (2024).</li>
<li>Yardeni, T., Eckhaus, M., Morris, H. D., Huizing, M., Hoogstraten-Miller, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Retro-orbital+injections+in+mice%5BTitle%5D)+AND+%22Lab+Anim%22%5BJournal%5D)">Retro-orbital injections in mice.</a> Lab Anim. 40 (5), 155-160 (2011).</li>
<li>Pavathuparambil, A. M. N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Facial+vein+injection+of+human+cells+in+severe+combined+immunodeficiency+%28SCID%29+neonatal+mice%5BTitle%5D)+AND+%22MethodsX%22%5BJournal%5D)">Facial vein injection of human cells in severe combined immunodeficiency (SCID) neonatal mice.</a> MethodsX. 5, 1281-1286 (2018).</li>
</ol>

The authors have nothing to disclose.

Understanding how early-life immune development influences cancer progression is essential for designing age-appropriate immunomodulatory strategies. In this study, we describe a reproducible neonatal transplantation platform that enables precise temporal control of cancer cell engraftment and immune modulation during a critical window of postnatal immune immaturity. By combining temporal vein&#8211;mediated intravenous delivery with BLI, this model allows systematic interrogation of how early-life infection shapes pedia...

Recent advances in immunotherapy have markedly enhanced outcomes for certain cancer patients, yet their optimal application in young children necessitates a thorough understanding of how the developing immune system identifies and eradicates cancer cells. While approximately 50% of childhood cancers originate in utero, including B-cell acute lymphoblastic leukemia (B-ALL) and NB, growing evidence suggests that postnatal events critically influence disease evolution and clinical outcome1,2.
Neonatal immune responses differ quantitatively and qualitatively from those of adults3. In the absence of fully developed adaptive immunity, protection of neonates relies&#160;heavily on maternal antibodies and innate immune cells. These innate effectors, however, are functionally less efficient than their adult counterparts due to cell-intrinsic hypo-responsiveness and enhanced activation of immunosuppressive pathways, leaving neonates particularly susceptible to infection4,5,6. However, the impact of these characteristics on the ability of the immature immune system to mount effective anti-cancer responses remains poorly understood.
Modeling anti-cancer immunity in early life requires the precise and reproducible delivery of cancer cells and immune modulators or pathogens during the short postnatal window, when immune function is limited. Temporal vein injection is a neonatal intravenous (IV) delivery method that best meets these requirements and offers high procedural success, low mortality, minimal handling stress, and compatibility with sequential interventions, such as infection challenge or therapeutic administration7,8,9,10.
In this study, we built upon and modified previously validated neonatal intravenous delivery techniques and the versatility of bioluminescent in vivo imaging to describe a transplant model to study the impact of early-life infection on the progression of pediatric cancer cells. This approach enables the intravenous delivery of luciferase-tagged B-ALL or NB cells to 1&#8211;2-day-old pups, followed by immune modulation through intraperitoneal (i.p.) administration of murine cytomegalovirus (mCMV) on postnatal day 7 (P7). Cancer progression was subsequently evaluated 10 days post-infection (P17).
Although access to the temporal vein is restricted to a limited postnatal window (P0&#8211;P3), this methodology enhances reproducibility and experimental control, offering a versatile platform to investigate the influence of early-life immune mechanisms on cancer immunosurveillance, infection&#8211;cancer interactions, and responses to immunotherapy. Additionally, this approach supports the efficient homing of transplanted cells, thereby enabling the reproducible establishment of disease models for mechanistic investigations.

<table><tbody><tr><td>100&amp;micro;L, Microliter Syringe, Luer Tip&amp;nbsp;</td><td>Hamilton&amp;nbsp;</td><td>&amp;nbsp;80601</td><td>&amp;nbsp;-</td></tr><tr><td>30 G Needle&amp;nbsp;</td><td>&amp;nbsp;BD&amp;nbsp;</td><td>&amp;nbsp;305106</td><td>&amp;nbsp;-</td></tr><tr><td>7-AAD&amp;nbsp;</td><td>Biolegend&amp;nbsp;</td><td>420404&amp;nbsp;</td><td>-&amp;nbsp;</td></tr><tr><td>Ami-X imaging system&amp;nbsp;</td><td>Spectral Instruments Imaging&amp;nbsp;</td><td>-&amp;nbsp;</td><td>-&amp;nbsp;</td></tr><tr><td>anti-mouse B220- APC&amp;nbsp;</td><td>Biolegend&amp;nbsp;</td><td>103212&amp;nbsp;</td><td>&amp;nbsp;-</td></tr><tr><td>anti-mouse CD19-FITC&amp;nbsp;</td><td>Biolegend&amp;nbsp;</td><td>152404&amp;nbsp;</td><td>&amp;nbsp;-</td></tr><tr><td>anti-mouse CD3&amp;epsilon;- PerCP</td><td>Biolegend &amp;nbsp;</td><td>100326&amp;nbsp;</td><td>-&amp;nbsp;</td></tr><tr><td>anti-mouse Ly-51-PE</td><td>Biolegend &amp;nbsp;</td><td>108308&amp;nbsp;</td><td>Also called BP1&amp;nbsp;</td></tr><tr><td>anti-mouse TER119- PerCP &amp;nbsp;</td><td>Biolegend&amp;nbsp;</td><td>116226&amp;nbsp;</td><td>-&amp;nbsp;</td></tr><tr><td>anti-mouse/human CD11b- PerCP&amp;nbsp;</td><td>Biolegend&amp;nbsp;</td><td>101230&amp;nbsp;</td><td>-&amp;nbsp;</td></tr><tr><td>Aura software&amp;nbsp;</td><td>Spectral Instruments Imaging&amp;nbsp;</td><td>-&amp;nbsp;</td><td>version 4.0.8</td></tr><tr><td>BD Accuri C6&amp;nbsp;</td><td>&amp;nbsp;BD</td><td>-&amp;nbsp;</td><td>-&amp;nbsp;</td></tr><tr><td>BD Fortessa X-20&amp;nbsp;</td><td>&amp;nbsp;BD</td><td>-&amp;nbsp;</td><td>-&amp;nbsp;</td></tr><tr><td>Cleaning solution&amp;nbsp;</td><td>Hamilton&amp;nbsp;</td><td>18310&amp;nbsp;</td><td>&amp;nbsp;-</td></tr><tr><td>CountBright Absolute Counting Beads&amp;nbsp;</td><td>Invitrogen by Thermo Fisher Scientific&amp;nbsp;</td><td>2770930&amp;nbsp;</td><td>6 &amp;micro;L contains 6000 beads&amp;nbsp;</td></tr><tr><td>D-Luciferin&amp;nbsp;</td><td>GoldBio</td><td>eLUCK-1G</td><td>-&amp;nbsp;</td></tr><tr><td>DMEM</td><td>Gibco</td><td>11965092</td><td>-</td></tr><tr><td>DNase I</td><td>Sigma</td><td>1.13E+10</td><td>-</td></tr><tr><td>Falcon 40&amp;micro;m Cell Strainer, Blue, Sterile, Individually Packaged&amp;nbsp;</td><td>FALCON&amp;nbsp;</td><td>352340&amp;nbsp;</td><td>-&amp;nbsp;</td></tr><tr><td>FBS</td><td>Gibco</td><td>A5256701</td><td>-&amp;nbsp;</td></tr><tr><td>FlowJo software</td><td>&amp;nbsp;BD</td><td>-&amp;nbsp;</td><td>v10.8</td></tr><tr><td>Geltrex&lt;sup&gt;TM&lt;/sup&gt;</td><td>Thermo Fisher Scientific&amp;nbsp;</td><td>A1413202</td><td>-&amp;nbsp;</td></tr><tr><td>GraphPad Prism software&amp;nbsp;</td><td>Dotmatics</td><td>-&amp;nbsp;</td><td>v10.4.1</td></tr><tr><td>LE.5209 Cold light source&amp;nbsp;</td><td>Euromex&amp;nbsp;</td><td>-</td><td>-&amp;nbsp;</td></tr><tr><td>Liberase&amp;trade; TM Research Grade</td><td>Sigma</td><td>5.4E+09</td><td>-</td></tr><tr><td>NSG mice</td><td>Jackson Labrotary</td><td>5557</td><td>NOD.Cg-Prkdcscid&amp;nbsp;Il2rgtm1Wjl/SzJ</td></tr><tr><td>Polybrene</td><td>Sigma</td><td>H9268-5G</td><td>-</td></tr><tr><td>Purified anti-mouse CD16/32 Antibody</td><td>Biolegend&amp;nbsp;</td><td>101301</td><td>-&amp;nbsp;</td></tr><tr><td>RBC Lysis Buffer (10X)</td><td>Biolegend&amp;nbsp;</td><td>420301</td><td>-&amp;nbsp;</td></tr></tbody></table>

a neonatal intravenous transplant model for assessment of early-life immune activities against cancer cells

A Neonatal Intravenous Transplant Model for Assessment of Early-Life Immune Activities Against Cancer Cells

More than half of all pediatric cancers are initiated in utero, with progression towards overt disease continuing through the neonatal period. While immunotherapies now offer new treatment options for many children with cancer, how early-life immunity influences cancer progression and therapy response remains incompletely understood. Addressing this gap will require evaluation of therapeutic interventions during the neonatal period, when immune responses differ fundamentally from those in later childhood and adulthood.
Here, we describe a neonatal transplantation model that integrates with bioluminescent in vivo imaging to investigate the impact of early-life immune modulation on&#160;pediatric cancers.
Temporal vein injection of luciferase-tagged cells derived from two in utero-initiated cancers achieved reproducible tumour engraftment in 1&#8211;2-day-old syngeneic recipients, with no procedure-related mortality and high procedural success as confirmed by bioluminescent imaging. Using infection-driven immune modulation as an experimental variable, we then show that intraperitoneal infection with murine cytomegalovirus five days after transplantation results in a marked reduction in the burden of acute lymphoblastic leukemia (ALL), but not neuroblastoma (NB). This platform enables the study of&#160;cancer-specific differences in response to early-life immune modulation and underscores the importance of tumor context when modeling immune&#8211;cancer interactions in early life.
Collectively, this methodology provides a versatile and highly reproducible platform for interrogating neonatal immune mechanisms relevant to cancer immunosurveillance, infection-driven immune modulation, and therapeutic intervention. Beyond ALL and NB, this approach can be adapted to additional pediatric malignancies and immunomodulatory strategies, supporting mechanistic studies and preclinical evaluation of early-life cancer interventions.

Temporal vein injection enables efficient neonatal engraftment of leukemia and neuroblastoma cells 
To model the impact of early-life infection on pediatric cancer progression, luciferase-tagged B-ALL cells derived from leukemic adult Eµ-Ret mice or NB cells derived from moribund Th-Mycn mice were intravenously delivered via the temporal vein into 1–2-day-old syngeneic pups. Successful engraftment was confirmed five days post-transplantation using BLI and X-ray imaging for both leukemia (<strong class...

This protocol demonstrates temporal vein injection for intravenous delivery of pediatric cancer cells to neonatal mice, enabling precise, reproducible modeling of early-life immune responses against cancer. The method enables assessment of the impact of interventions, such as immunomodulation or therapy, when applied during the neonatal period.

More than half of all pediatric cancers are initiated in utero, with progression towards overt disease continuing through the neonatal period. While ...

We study how early life immunity influences pediatric cancer progression and whether neonatal immune responses can suppress or promote cancer progression. Current models lack precise neonatal intravenous delivery. This protocol ensures efficient delivery and consistent modeling of early life immune responses.To begin, place freshly-prepared suspensions of luciferase-tagged leukemic cells derived from E mu-retin mice or neuroblastoma cells derived from Th-MYCN mice on ice before neonatal transplantation. Load 60 microliters of the cell suspension into a 100-microliter glass syringe. Then attach a 30-gauge needle.Expel the suspension back into the tube to fill the dead volume of the syringe and needle. Then aspirate 20 microliters of the cell suspension containing either 1 times 10 to the power of 4 leukemic cells for BALB/c recipients or 5 times 10 to the power of 4 neuroblastoma cells for Th-MYCN recipients ensuring no air bubbles are introduced. Prepare a transilluminated stage by placing a cold light source beneath a plexiglass platform.Next, place a sterile napkin with a central hole on the stage. Wear magnifying eyewear to visualize the injection site. Then place a small piece of modeling clay to stabilize the needle during injection.Position the hypothermia-immobilized postnatal day one or two pup on the napkin and adjust its position until the temporal vein is clearly visible. Then insert the needle, bevel up, into the visible temporal vein, and push the plunger to slowly inject the cell suspension. Observe vascular filling to confirm successful intravenous delivery.Apply gentle pressure to the injection site using a sterile cotton swab. Then place the pup on a warmed recovery surface at approximately 37 degrees Celsius with a towel barrier. Allow recovery until normal movement and pink coloration return.Monitor the pup for 5 to 10 minutes after recovery, and return the pup to the dam. Rinse the syringe with PBS followed by a syringe-cleaning solution. And finally, with 70%ethanol.Prepare the pup for bioluminescence imaging six days after the temporal vein injection. Retrieve an aliquot of filter-sterilized D-luciferin from the freezer. Using a 30-gauge needle, inject the pup with 50 microliters of D-luciferin intraperitoneally.Next, place the anesthetized pup on a warmed imaging stage at approximately 37 degrees Celsius. 10 minutes after the injection, acquire bioluminescence and x-ray images using consistent exposure settings. Set the exposure time to 120 seconds.Use medium binning, and set the x-ray power level to high. Intraperitoneally inject postnatal day-seven pups with murine cytomegalovirus, or MCMV, six days after temporal vein transplantation of cancer cells. Repeat the bioluminescence imaging procedure, 10 days post-viral injection, to evaluate the effect of infection-driven immune activation on tumor progression.Then define whole body regions of interest for each mouse using bioluminescence imaging software and quantify the emitted light. Finally, export the quantified region of interest values for downstream statistical analysis. Bioluminescence imaging, combined with x-ray imaging, confirmed successful engraftment of leukemic cells and neuroblastoma cells at postnatal day seven, revealing that temporal vein injection achieved 100%procedural success.MCMV-infected mice showed a significant reduction in leukemia burden at postnatal day 17 compared with control mice. Quantification of bioluminescent signal demonstrated a significant reduction in leukemic burden in MCMV-infected mice compared with controls at postnatal day 17. Flow cytometric quantification showed significantly fewer leukemic cells in the spleen and bone marrow of MCMV-treated mice compared with controls.In contrast, the neuroblastoma burden at postnatal day 17 was comparable between MCMV-infected mice and control mice. This protocol enables longitudinal tracking of cancer progression and evaluation of early life immune modulation using bioluminescence imaging. The main challenge is accurate temporal vein injection within a narrow neonatal window, requiring careful technique and proper visualization.Future studies can explore different pediatric cancers and immune stimuli, vaccines, or therapies to define mechanisms of immune-mediated cancer control in early life.

a-neonatal-intravenous-transplant-model-for-assessment-early-life

Research

JoVE Journal

Immunology and Infection

Murine bone marrow transplantation is a widely used technique to study immunological mechanisms governing graft-versus-host disease in humans.  The ability to monitor T cell trafficking patterns in vivo allows for detailed analysis of the development and perpetuation of T cell responses during graft-versus-host disease.

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model

Novel generations of functional assays such as gamma interferon (IFN-γ) ELISpot, which detect cytokine production at the single cell level and provide both quantitative and qualitative characterization of T cell responses can be used to assess cell-mediated immune responses directed against varicella zoster virus (VZV).

Development of an IFN-&#947; ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Animal models of pediatric disease can experience early onset and aggressive disease progression. Clinically relevant therapy delivery to young mouse models can be technically difficult. This protocol describes a non-invasive intravenous injection method for newborn mice within the first two postnatal days of life.

Intravenous Injections in Neonatal Mice

Here, we present a protocol to induce tolerance in transplantation, and assess in vitro and in vivo the suppressive capacity of distinct cell subsets from the recipient and the immune status of the recipient toward donor or exogenous antigens.

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

We describe a protocol for performing an in utero transplantation (IUT) through intravenous and intra-amniotic routes of injection in the murine model. This protocol can be used to introduce cells, viral vectors, and other substances into the unique immune-tolerant fetal environment.

Intravenous and Intra-amniotic In Utero Transplantation in the Murine Model

We describe here a flow cytometry-based in vivo killing assay that enables examination of immunodominance in cytotoxic T lymphocyte (CTL) responses to a model tumor antigen. We provide examples of how this elegant assay may be employed for mechanistic studies and for drug efficacy testing.

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

We describe a human peripheral blood mononuclear cell (PBMC) — based humanized xenograft mouse model for translational immuno-oncology research. This protocol could serve as a general guideline for establishing and characterizing similar models for I-O therapy assessment.

A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research

Here, we present a tumor transplantation protocol for the characterization of tumor-inherent and periphery-derived tumor-infiltrated lymphocytes in a mouse tumor model. Specific tracing of the influx of recipient-derived immune cells with flow cytometry reveals the dynamics of the phenotypic and functional changes of these cells during antitumor immune responses.

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

This protocol describes a straightforward and minimally invasive method for transplanting and imaging NIT-1 cells in non-obese diabetic (NOD)-severe combined immunodeficient mice challenged with splenocytes purified from spontaneously diabetic NOD mice.

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

This protocol provides step-by-step instructions for generating and troubleshooting human acute lymphoblastic leukemia (ALL) xenografts from cell lines and fresh patient material in transiently immunosuppressed zebrafish embryos, along with guidelines for drug response assessment using flow cytometry. The experimental pipeline can also be adapted for solid tumors.

Rapid in vivo Drug Response Prediction Using Leukemia Cell Grafts in Zebrafish Embryos

Learn a neonatal intravenous transplant model using bioluminescent imaging to study early-life immune modulation against pediatric cancer cells in mice. This method enables reproducible tumor engraftment and longitudinal tracking.

A Neonatal Intravenous Transplant Model for Assessment of Early-Life Immune Activities Against Cancer Cells

Explore More Videos